Chill Brands and SYP Global Develop Novel Nicotine Delivery System, Expected to Launch Within 12 Months

Sep.09.2025
Chill Brands Group has formed a strategic partnership with SYP Global, which is developing a heating-free nicotine delivery technology designed to reduce harmful by-products. Chill Brands will support SYP’s market entry through its distribution network, though commercial launch is expected within 12 months with no immediate revenue impact.

Key Points:

 

·SYP is developing a novel nicotine delivery technology that differs significantly from conventional e-cigarette systems.

·Chill Brands responsible for supporting the development of SYP and facilitating its route to market through Chill Connect's established distribution network. 

·Market trials are planned, but regulatory approval and commercial success are not guaranteed.

 


 

2Firsts, September 9th - according to london stock exchange reported in September 8th, Chill Brands Group plc (LSE: CHLL) has entered a strategic partnership with SYP Global Limited, a company developing an innovative nicotine delivery system. Unlike conventional vaping products, SYP’s technology does not use heating elements or traditional solvents, thereby avoiding harmful by-products such as carbonyl compounds and metallic particles. This approach is expected to offer a cleaner aerosol and smoother user experience.

 

As SYP’s brand expansion partner, Chill Brands will support market entry through its Chill Connect distribution network. CEO Callum Sommerton will join SYP’s board to assist in commercialization and intellectual property protection. The technology is still in development and is anticipated to be commercially available within 12 months. No immediate revenue is expected, and Chill Brands has not made any equity investment in SYP.

 

Both companies view the partnership as a high-potential opportunity to introduce a novel nicotine alternative. Chill Brands will leverage its retail network to support in-market trials and eventual distribution across the UK.

 

UK’s North Yorkshire Council plans up to £477,000 spend on e-cigarettes to support quitting smoking
UK’s North Yorkshire Council plans up to £477,000 spend on e-cigarettes to support quitting smoking
North Yorkshire Council in the UK is set to spend up to £477,000 on e-cigarettes to support residents quitting smoking. Since e-cigarettes were added to the council’s Living Well Smokefree service in July 2023, 487 people have used them to quit, with about a third remaining smoke-free after a year.
Mar.03 by 2FIRSTS.ai
France’s ANSES warns vaping carries health risks, urges limiting e-cigarette use to smoking cessation
France’s ANSES warns vaping carries health risks, urges limiting e-cigarette use to smoking cessation
France’s National Agency for Food, Environmental and Occupational Health & Safety (ANSES) says vaping poses health risks because users inhale toxic or harmful substances, even if e-cigarettes are generally considered less harmful than cigarettes.
Feb.04 by 2FIRSTS.ai
UK Barnsley: Town-centre vape shop and owner hit with £15,000+ bill after ignoring three improvement notices
UK Barnsley: Town-centre vape shop and owner hit with £15,000+ bill after ignoring three improvement notices
A Barnsley town-centre vape retailer and its owner have been ordered to pay more than £15,000 after admitting multiple offences linked to the continued sale of illegal single-use vapes and non-compliant food items, despite three formal improvement notices.
Feb.06 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai
2Firsts|Sesh Advances Nicotine Pouch PMTA to Filing Stage, Experts Highlight Regulatory Threshold and Market Window
2Firsts|Sesh Advances Nicotine Pouch PMTA to Filing Stage, Experts Highlight Regulatory Threshold and Market Window
Sesh said its Premarket Tobacco Product Application (PMTA) for 64 nicotine pouch SKUs has been accepted by the U.S. Food and Drug Administration (FDA) and advanced to the Filing stage, entering substantive scientific review. Industry experts say the development signals that the application has crossed a key technical and regulatory threshold, while also highlighting growing divergence in regulatory capability and market positioning within the nicotine pouch category.
Special Report
Mar.24 by 2FIRSTS.ai